nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycopyrrolate—Abnormal behaviour—Temozolomide—melanoma	0.0149	0.0269	CcSEcCtD
Glycopyrrolate—Atrial fibrillation—Vemurafenib—melanoma	0.00832	0.015	CcSEcCtD
Glycopyrrolate—Pain in extremity—Vemurafenib—melanoma	0.00788	0.0142	CcSEcCtD
Glycopyrrolate—Aggression—Bleomycin—melanoma	0.00749	0.0135	CcSEcCtD
Glycopyrrolate—Dry skin—Vemurafenib—melanoma	0.00722	0.0131	CcSEcCtD
Glycopyrrolate—Cystitis noninfective—Bleomycin—melanoma	0.00642	0.0116	CcSEcCtD
Glycopyrrolate—Cystitis—Bleomycin—melanoma	0.00635	0.0115	CcSEcCtD
Glycopyrrolate—Hexylcaine—SCN10A—melanoma	0.00614	1	CrCbGaD
Glycopyrrolate—Infestation NOS—Vemurafenib—melanoma	0.00607	0.011	CcSEcCtD
Glycopyrrolate—Infestation—Vemurafenib—melanoma	0.00607	0.011	CcSEcCtD
Glycopyrrolate—Bladder pain—Bleomycin—melanoma	0.00595	0.0107	CcSEcCtD
Glycopyrrolate—Injection site reaction—Carmustine—melanoma	0.00571	0.0103	CcSEcCtD
Glycopyrrolate—Intestinal obstruction—Docetaxel—melanoma	0.00541	0.00978	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Vemurafenib—melanoma	0.00536	0.00968	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Vemurafenib—melanoma	0.00506	0.00914	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Vemurafenib—melanoma	0.00491	0.00888	CcSEcCtD
Glycopyrrolate—Malnutrition—Vemurafenib—melanoma	0.00475	0.00858	CcSEcCtD
Glycopyrrolate—Erythema—Vemurafenib—melanoma	0.00475	0.00858	CcSEcCtD
Glycopyrrolate—Dysgeusia—Vemurafenib—melanoma	0.00465	0.0084	CcSEcCtD
Glycopyrrolate—Ageusia—Docetaxel—melanoma	0.00455	0.00823	CcSEcCtD
Glycopyrrolate—Gastroenteritis—Temozolomide—melanoma	0.00454	0.00821	CcSEcCtD
Glycopyrrolate—Nasal congestion—Temozolomide—melanoma	0.00442	0.00799	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00401	0.00725	CcSEcCtD
Glycopyrrolate—Affect lability—Temozolomide—melanoma	0.00396	0.00716	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Vemurafenib—melanoma	0.00387	0.007	CcSEcCtD
Glycopyrrolate—Infection—Vemurafenib—melanoma	0.00385	0.00695	CcSEcCtD
Glycopyrrolate—Mood swings—Temozolomide—melanoma	0.00382	0.00689	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Vemurafenib—melanoma	0.0038	0.00686	CcSEcCtD
Glycopyrrolate—Skin disorder—Vemurafenib—melanoma	0.00376	0.0068	CcSEcCtD
Glycopyrrolate—Dehydration—Temozolomide—melanoma	0.00375	0.00677	CcSEcCtD
Glycopyrrolate—Pneumonia—Bleomycin—melanoma	0.0037	0.00669	CcSEcCtD
Glycopyrrolate—Dry skin—Temozolomide—melanoma	0.00369	0.00667	CcSEcCtD
Glycopyrrolate—Injection site reaction—Docetaxel—melanoma	0.00367	0.00663	CcSEcCtD
Glycopyrrolate—Hypotension—Vemurafenib—melanoma	0.00362	0.00654	CcSEcCtD
Glycopyrrolate—Abdominal distension—Temozolomide—melanoma	0.0035	0.00633	CcSEcCtD
Glycopyrrolate—Pneumonia—Dactinomycin—melanoma	0.00345	0.00624	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Vemurafenib—melanoma	0.00334	0.00604	CcSEcCtD
Glycopyrrolate—Fatigue—Vemurafenib—melanoma	0.00334	0.00603	CcSEcCtD
Glycopyrrolate—Constipation—Vemurafenib—melanoma	0.00331	0.00598	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Bleomycin—melanoma	0.00329	0.00594	CcSEcCtD
Glycopyrrolate—Dysuria—Temozolomide—melanoma	0.00326	0.00588	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Carmustine—melanoma	0.00325	0.00587	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Temozolomide—melanoma	0.00324	0.00585	CcSEcCtD
Glycopyrrolate—Pneumonia—Carmustine—melanoma	0.00323	0.00584	CcSEcCtD
Glycopyrrolate—Erectile dysfunction—Temozolomide—melanoma	0.00321	0.00579	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Temozolomide—melanoma	0.00314	0.00567	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Carmustine—melanoma	0.00312	0.00564	CcSEcCtD
Glycopyrrolate—Pneumonia—Temozolomide—melanoma	0.00312	0.00564	CcSEcCtD
Glycopyrrolate—Infestation NOS—Temozolomide—melanoma	0.0031	0.00561	CcSEcCtD
Glycopyrrolate—Infestation—Temozolomide—melanoma	0.0031	0.00561	CcSEcCtD
Glycopyrrolate—Flushing—Bleomycin—melanoma	0.00307	0.00554	CcSEcCtD
Glycopyrrolate—Body temperature increased—Vemurafenib—melanoma	0.00306	0.00553	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Temozolomide—melanoma	0.00302	0.00545	CcSEcCtD
Glycopyrrolate—Sinusitis—Temozolomide—melanoma	0.00291	0.00526	CcSEcCtD
Glycopyrrolate—Erythema—Bleomycin—melanoma	0.00288	0.0052	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Carmustine—melanoma	0.00287	0.00518	CcSEcCtD
Glycopyrrolate—Flushing—Dactinomycin—melanoma	0.00286	0.00517	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Vemurafenib—melanoma	0.00285	0.00516	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Carmustine—melanoma	0.00283	0.00512	CcSEcCtD
Glycopyrrolate—Atrial fibrillation—Docetaxel—melanoma	0.00283	0.00511	CcSEcCtD
Glycopyrrolate—Asthenia—Vemurafenib—melanoma	0.00278	0.00502	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Temozolomide—melanoma	0.00277	0.00501	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Temozolomide—melanoma	0.00275	0.00497	CcSEcCtD
Glycopyrrolate—Pruritus—Vemurafenib—melanoma	0.00274	0.00495	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Temozolomide—melanoma	0.00274	0.00495	CcSEcCtD
Glycopyrrolate—Urethral disorder—Temozolomide—melanoma	0.00273	0.00493	CcSEcCtD
Glycopyrrolate—Erythema—Dactinomycin—melanoma	0.00268	0.00485	CcSEcCtD
Glycopyrrolate—Pain in extremity—Docetaxel—melanoma	0.00268	0.00484	CcSEcCtD
Glycopyrrolate—Flushing—Carmustine—melanoma	0.00268	0.00483	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Temozolomide—melanoma	0.00259	0.00467	CcSEcCtD
Glycopyrrolate—Flushing—Temozolomide—melanoma	0.00259	0.00467	CcSEcCtD
Glycopyrrolate—Dizziness—Vemurafenib—melanoma	0.00256	0.00463	CcSEcCtD
Glycopyrrolate—Mental disorder—Carmustine—melanoma	0.00253	0.00456	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Temozolomide—melanoma	0.00251	0.00454	CcSEcCtD
Glycopyrrolate—Erythema—Carmustine—melanoma	0.00251	0.00453	CcSEcCtD
Glycopyrrolate—Malnutrition—Carmustine—melanoma	0.00251	0.00453	CcSEcCtD
Glycopyrrolate—Dehydration—Docetaxel—melanoma	0.00249	0.0045	CcSEcCtD
Glycopyrrolate—Vomiting—Vemurafenib—melanoma	0.00246	0.00445	CcSEcCtD
Glycopyrrolate—Dry skin—Docetaxel—melanoma	0.00246	0.00444	CcSEcCtD
Glycopyrrolate—Rash—Vemurafenib—melanoma	0.00244	0.00441	CcSEcCtD
Glycopyrrolate—Mental disorder—Temozolomide—melanoma	0.00244	0.00441	CcSEcCtD
Glycopyrrolate—Dermatitis—Vemurafenib—melanoma	0.00244	0.00441	CcSEcCtD
Glycopyrrolate—Headache—Vemurafenib—melanoma	0.00243	0.00438	CcSEcCtD
Glycopyrrolate—Erythema—Temozolomide—melanoma	0.00243	0.00438	CcSEcCtD
Glycopyrrolate—Malnutrition—Temozolomide—melanoma	0.00243	0.00438	CcSEcCtD
Glycopyrrolate—Nasopharyngitis—Docetaxel—melanoma	0.0024	0.00433	CcSEcCtD
Glycopyrrolate—Dysgeusia—Temozolomide—melanoma	0.00238	0.00429	CcSEcCtD
Glycopyrrolate—Confusional state—Bleomycin—melanoma	0.00237	0.00428	CcSEcCtD
Glycopyrrolate—Vision blurred—Carmustine—melanoma	0.00237	0.00427	CcSEcCtD
Glycopyrrolate—Oedema—Bleomycin—melanoma	0.00235	0.00424	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Bleomycin—melanoma	0.00235	0.00424	CcSEcCtD
Glycopyrrolate—Infection—Bleomycin—melanoma	0.00233	0.00421	CcSEcCtD
Glycopyrrolate—Agitation—Carmustine—melanoma	0.00231	0.00417	CcSEcCtD
Glycopyrrolate—Nausea—Vemurafenib—melanoma	0.0023	0.00416	CcSEcCtD
Glycopyrrolate—Vision blurred—Temozolomide—melanoma	0.00229	0.00413	CcSEcCtD
Glycopyrrolate—Agitation—Temozolomide—melanoma	0.00223	0.00403	CcSEcCtD
Glycopyrrolate—Hypotension—Bleomycin—melanoma	0.00219	0.00396	CcSEcCtD
Glycopyrrolate—Oedema—Dactinomycin—melanoma	0.00219	0.00395	CcSEcCtD
Glycopyrrolate—Convulsion—Carmustine—melanoma	0.00217	0.00393	CcSEcCtD
Glycopyrrolate—Infection—Dactinomycin—melanoma	0.00217	0.00393	CcSEcCtD
Glycopyrrolate—Hypertension—Carmustine—melanoma	0.00217	0.00392	CcSEcCtD
Glycopyrrolate—Palpitations—Temozolomide—melanoma	0.00214	0.00387	CcSEcCtD
Glycopyrrolate—Convulsion—Temozolomide—melanoma	0.0021	0.0038	CcSEcCtD
Glycopyrrolate—Hypertension—Temozolomide—melanoma	0.00209	0.00378	CcSEcCtD
Glycopyrrolate—Pneumonia—Docetaxel—melanoma	0.00208	0.00375	CcSEcCtD
Glycopyrrolate—Confusional state—Carmustine—melanoma	0.00207	0.00373	CcSEcCtD
Glycopyrrolate—Infestation—Docetaxel—melanoma	0.00206	0.00373	CcSEcCtD
Glycopyrrolate—Infestation NOS—Docetaxel—melanoma	0.00206	0.00373	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00205	0.00371	CcSEcCtD
Glycopyrrolate—Oedema—Carmustine—melanoma	0.00205	0.0037	CcSEcCtD
Glycopyrrolate—Infection—Carmustine—melanoma	0.00204	0.00368	CcSEcCtD
Glycopyrrolate—Dry mouth—Temozolomide—melanoma	0.00202	0.00365	CcSEcCtD
Glycopyrrolate—Pain—Bleomycin—melanoma	0.00201	0.00363	CcSEcCtD
Glycopyrrolate—Tachycardia—Carmustine—melanoma	0.002	0.00361	CcSEcCtD
Glycopyrrolate—Confusional state—Temozolomide—melanoma	0.002	0.00361	CcSEcCtD
Glycopyrrolate—Oedema—Temozolomide—melanoma	0.00198	0.00358	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Temozolomide—melanoma	0.00198	0.00358	CcSEcCtD
Glycopyrrolate—Infection—Temozolomide—melanoma	0.00197	0.00355	CcSEcCtD
Glycopyrrolate—Epistaxis—Docetaxel—melanoma	0.00195	0.00352	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Temozolomide—melanoma	0.00194	0.00351	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Bleomycin—melanoma	0.00193	0.00349	CcSEcCtD
Glycopyrrolate—Skin disorder—Temozolomide—melanoma	0.00192	0.00347	CcSEcCtD
Glycopyrrolate—Hypotension—Carmustine—melanoma	0.00191	0.00346	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Temozolomide—melanoma	0.00191	0.00346	CcSEcCtD
Glycopyrrolate—Fatigue—Dactinomycin—melanoma	0.00189	0.00341	CcSEcCtD
Glycopyrrolate—Pain—Dactinomycin—melanoma	0.00187	0.00338	CcSEcCtD
Glycopyrrolate—Urticaria—Bleomycin—melanoma	0.00186	0.00337	CcSEcCtD
Glycopyrrolate—Rhinitis—Docetaxel—melanoma	0.00186	0.00336	CcSEcCtD
Glycopyrrolate—Body temperature increased—Bleomycin—melanoma	0.00186	0.00335	CcSEcCtD
Glycopyrrolate—Insomnia—Carmustine—melanoma	0.00185	0.00335	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Docetaxel—melanoma	0.00184	0.00333	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Docetaxel—melanoma	0.00183	0.00331	CcSEcCtD
Glycopyrrolate—Somnolence—Carmustine—melanoma	0.00182	0.00329	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Docetaxel—melanoma	0.00182	0.00329	CcSEcCtD
Glycopyrrolate—Urethral disorder—Docetaxel—melanoma	0.00182	0.00328	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Dactinomycin—melanoma	0.0018	0.00326	CcSEcCtD
Glycopyrrolate—Insomnia—Temozolomide—melanoma	0.00179	0.00323	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Dactinomycin—melanoma	0.00179	0.00323	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Carmustine—melanoma	0.00177	0.0032	CcSEcCtD
Glycopyrrolate—Somnolence—Temozolomide—melanoma	0.00176	0.00318	CcSEcCtD
Glycopyrrolate—Constipation—Carmustine—melanoma	0.00175	0.00317	CcSEcCtD
Glycopyrrolate—Pain—Carmustine—melanoma	0.00175	0.00317	CcSEcCtD
Glycopyrrolate—Dyspepsia—Temozolomide—melanoma	0.00174	0.00315	CcSEcCtD
Glycopyrrolate—Body temperature increased—Dactinomycin—melanoma	0.00173	0.00313	CcSEcCtD
Glycopyrrolate—Abdominal pain—Dactinomycin—melanoma	0.00173	0.00313	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Bleomycin—melanoma	0.00173	0.00312	CcSEcCtD
Glycopyrrolate—Flushing—Docetaxel—melanoma	0.00172	0.00311	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Docetaxel—melanoma	0.00172	0.00311	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Temozolomide—melanoma	0.00171	0.00309	CcSEcCtD
Glycopyrrolate—Fatigue—Temozolomide—melanoma	0.00171	0.00308	CcSEcCtD
Glycopyrrolate—Pain—Temozolomide—melanoma	0.00169	0.00306	CcSEcCtD
Glycopyrrolate—Constipation—Temozolomide—melanoma	0.00169	0.00306	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Carmustine—melanoma	0.00169	0.00305	CcSEcCtD
Glycopyrrolate—Asthenia—Bleomycin—melanoma	0.00168	0.00304	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Carmustine—melanoma	0.00168	0.00303	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Docetaxel—melanoma	0.00167	0.00302	CcSEcCtD
Glycopyrrolate—Pruritus—Bleomycin—melanoma	0.00166	0.003	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Temozolomide—melanoma	0.00163	0.00295	CcSEcCtD
Glycopyrrolate—Mental disorder—Docetaxel—melanoma	0.00162	0.00293	CcSEcCtD
Glycopyrrolate—Abdominal pain—Carmustine—melanoma	0.00162	0.00293	CcSEcCtD
Glycopyrrolate—Body temperature increased—Carmustine—melanoma	0.00162	0.00293	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Temozolomide—melanoma	0.00162	0.00292	CcSEcCtD
Glycopyrrolate—Malnutrition—Docetaxel—melanoma	0.00161	0.00291	CcSEcCtD
Glycopyrrolate—Erythema—Docetaxel—melanoma	0.00161	0.00291	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Dactinomycin—melanoma	0.00161	0.00291	CcSEcCtD
Glycopyrrolate—Dysgeusia—Docetaxel—melanoma	0.00158	0.00285	CcSEcCtD
Glycopyrrolate—Urticaria—Temozolomide—melanoma	0.00157	0.00284	CcSEcCtD
Glycopyrrolate—Asthenia—Dactinomycin—melanoma	0.00157	0.00284	CcSEcCtD
Glycopyrrolate—Abdominal pain—Temozolomide—melanoma	0.00156	0.00283	CcSEcCtD
Glycopyrrolate—Body temperature increased—Temozolomide—melanoma	0.00156	0.00283	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Carmustine—melanoma	0.00151	0.00273	CcSEcCtD
Glycopyrrolate—Vomiting—Bleomycin—melanoma	0.00149	0.0027	CcSEcCtD
Glycopyrrolate—Rash—Bleomycin—melanoma	0.00148	0.00267	CcSEcCtD
Glycopyrrolate—Dermatitis—Bleomycin—melanoma	0.00148	0.00267	CcSEcCtD
Glycopyrrolate—Asthenia—Carmustine—melanoma	0.00147	0.00266	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Temozolomide—melanoma	0.00146	0.00264	CcSEcCtD
Glycopyrrolate—Palpitations—Docetaxel—melanoma	0.00143	0.00258	CcSEcCtD
Glycopyrrolate—Asthenia—Temozolomide—melanoma	0.00142	0.00257	CcSEcCtD
Glycopyrrolate—Pruritus—Temozolomide—melanoma	0.0014	0.00253	CcSEcCtD
Glycopyrrolate—Convulsion—Docetaxel—melanoma	0.0014	0.00253	CcSEcCtD
Glycopyrrolate—Nausea—Bleomycin—melanoma	0.00139	0.00252	CcSEcCtD
Glycopyrrolate—Hypertension—Docetaxel—melanoma	0.00139	0.00252	CcSEcCtD
Glycopyrrolate—Vomiting—Dactinomycin—melanoma	0.00139	0.00251	CcSEcCtD
Glycopyrrolate—Rash—Dactinomycin—melanoma	0.00138	0.00249	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00136	0.00246	CcSEcCtD
Glycopyrrolate—Dizziness—Carmustine—melanoma	0.00135	0.00245	CcSEcCtD
Glycopyrrolate—Dry mouth—Docetaxel—melanoma	0.00134	0.00243	CcSEcCtD
Glycopyrrolate—Confusional state—Docetaxel—melanoma	0.00133	0.0024	CcSEcCtD
Glycopyrrolate—Oedema—Docetaxel—melanoma	0.00132	0.00238	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Docetaxel—melanoma	0.00132	0.00238	CcSEcCtD
Glycopyrrolate—Dizziness—Temozolomide—melanoma	0.00131	0.00237	CcSEcCtD
Glycopyrrolate—Infection—Docetaxel—melanoma	0.00131	0.00236	CcSEcCtD
Glycopyrrolate—Vomiting—Carmustine—melanoma	0.0013	0.00235	CcSEcCtD
Glycopyrrolate—Nausea—Dactinomycin—melanoma	0.0013	0.00235	CcSEcCtD
Glycopyrrolate—Rash—Carmustine—melanoma	0.00129	0.00233	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Docetaxel—melanoma	0.00129	0.00233	CcSEcCtD
Glycopyrrolate—Dermatitis—Carmustine—melanoma	0.00129	0.00233	CcSEcCtD
Glycopyrrolate—Tachycardia—Docetaxel—melanoma	0.00128	0.00232	CcSEcCtD
Glycopyrrolate—Headache—Carmustine—melanoma	0.00128	0.00232	CcSEcCtD
Glycopyrrolate—Skin disorder—Docetaxel—melanoma	0.00128	0.00231	CcSEcCtD
Glycopyrrolate—Vomiting—Temozolomide—melanoma	0.00126	0.00227	CcSEcCtD
Glycopyrrolate—Rash—Temozolomide—melanoma	0.00125	0.00226	CcSEcCtD
Glycopyrrolate—Dermatitis—Temozolomide—melanoma	0.00125	0.00225	CcSEcCtD
Glycopyrrolate—Headache—Temozolomide—melanoma	0.00124	0.00224	CcSEcCtD
Glycopyrrolate—Hypotension—Docetaxel—melanoma	0.00123	0.00222	CcSEcCtD
Glycopyrrolate—Nausea—Carmustine—melanoma	0.00122	0.0022	CcSEcCtD
Glycopyrrolate—Insomnia—Docetaxel—melanoma	0.00119	0.00215	CcSEcCtD
Glycopyrrolate—Nausea—Temozolomide—melanoma	0.00118	0.00212	CcSEcCtD
Glycopyrrolate—Somnolence—Docetaxel—melanoma	0.00117	0.00211	CcSEcCtD
Glycopyrrolate—Dyspepsia—Docetaxel—melanoma	0.00116	0.00209	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Docetaxel—melanoma	0.00114	0.00205	CcSEcCtD
Glycopyrrolate—Fatigue—Docetaxel—melanoma	0.00113	0.00205	CcSEcCtD
Glycopyrrolate—Constipation—Docetaxel—melanoma	0.00113	0.00203	CcSEcCtD
Glycopyrrolate—Pain—Docetaxel—melanoma	0.00113	0.00203	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Docetaxel—melanoma	0.00108	0.00196	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Docetaxel—melanoma	0.00108	0.00195	CcSEcCtD
Glycopyrrolate—Abdominal pain—Docetaxel—melanoma	0.00104	0.00188	CcSEcCtD
Glycopyrrolate—Body temperature increased—Docetaxel—melanoma	0.00104	0.00188	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Docetaxel—melanoma	0.00097	0.00175	CcSEcCtD
Glycopyrrolate—Asthenia—Docetaxel—melanoma	0.000945	0.00171	CcSEcCtD
Glycopyrrolate—Pruritus—Docetaxel—melanoma	0.000931	0.00168	CcSEcCtD
Glycopyrrolate—Dizziness—Docetaxel—melanoma	0.000871	0.00157	CcSEcCtD
Glycopyrrolate—Vomiting—Docetaxel—melanoma	0.000837	0.00151	CcSEcCtD
Glycopyrrolate—Rash—Docetaxel—melanoma	0.00083	0.0015	CcSEcCtD
Glycopyrrolate—Dermatitis—Docetaxel—melanoma	0.000829	0.0015	CcSEcCtD
Glycopyrrolate—Headache—Docetaxel—melanoma	0.000825	0.00149	CcSEcCtD
Glycopyrrolate—Nausea—Docetaxel—melanoma	0.000782	0.00141	CcSEcCtD
Glycopyrrolate—CHRM2—Signaling Pathways—ITGB3—melanoma	6.39e-05	0.000145	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PRKCA—melanoma	6.39e-05	0.000145	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MAP2K1—melanoma	6.37e-05	0.000145	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—SPP1—melanoma	6.34e-05	0.000144	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3CD—melanoma	6.33e-05	0.000144	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—FGF2—melanoma	6.33e-05	0.000144	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MAP2K2—melanoma	6.32e-05	0.000144	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—SPP1—melanoma	6.32e-05	0.000144	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—CXCL8—melanoma	6.32e-05	0.000143	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MAP2K2—melanoma	6.3e-05	0.000143	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—CXCL8—melanoma	6.3e-05	0.000143	CbGpPWpGaD
Glycopyrrolate—CHRM5—GPCR downstream signaling—PIK3CA—melanoma	6.27e-05	0.000142	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—SPP1—melanoma	6.26e-05	0.000142	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MAP2K2—melanoma	6.24e-05	0.000142	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—CXCL8—melanoma	6.23e-05	0.000142	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—KRAS—melanoma	6.19e-05	0.000141	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—FGF2—melanoma	6.06e-05	0.000138	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CG—melanoma	6.04e-05	0.000137	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—IL2—melanoma	6.04e-05	0.000137	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—IL2—melanoma	6.02e-05	0.000137	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—TERT—melanoma	6.01e-05	0.000137	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—RAC1—melanoma	6e-05	0.000136	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—TERT—melanoma	6e-05	0.000136	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—RAC1—melanoma	5.98e-05	0.000136	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—IL2—melanoma	5.96e-05	0.000135	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—PIK3CA—melanoma	5.94e-05	0.000135	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—TERT—melanoma	5.94e-05	0.000135	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—RAC1—melanoma	5.92e-05	0.000134	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MDM2—melanoma	5.92e-05	0.000134	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—ERBB2—melanoma	5.84e-05	0.000132	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PPARG—melanoma	5.83e-05	0.000132	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PIK3CB—melanoma	5.76e-05	0.000131	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—HIF1A—melanoma	5.75e-05	0.000131	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—HIF1A—melanoma	5.73e-05	0.00013	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—PIK3CA—melanoma	5.69e-05	0.000129	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—HIF1A—melanoma	5.68e-05	0.000129	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MDM2—melanoma	5.67e-05	0.000129	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—ERBB2—melanoma	5.59e-05	0.000127	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CXCL8—melanoma	5.53e-05	0.000126	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3CB—melanoma	5.51e-05	0.000125	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—KDR—melanoma	5.5e-05	0.000125	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—HRAS—melanoma	5.5e-05	0.000125	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—KDR—melanoma	5.48e-05	0.000125	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—KDR—melanoma	5.43e-05	0.000123	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CDKN1B—melanoma	5.4e-05	0.000123	CbGpPWpGaD
Glycopyrrolate—CHRM4—GPCR downstream signaling—AKT1—melanoma	5.35e-05	0.000121	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CD—melanoma	5.31e-05	0.000121	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CXCL8—melanoma	5.3e-05	0.00012	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CASP3—melanoma	5.3e-05	0.00012	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—FN1—melanoma	5.29e-05	0.00012	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—IL2—melanoma	5.29e-05	0.00012	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—FN1—melanoma	5.28e-05	0.00012	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—HRAS—melanoma	5.26e-05	0.00012	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—IL6—melanoma	5.26e-05	0.000119	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—ALB—melanoma	5.24e-05	0.000119	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—FN1—melanoma	5.23e-05	0.000119	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—NOTCH1—melanoma	5.18e-05	0.000118	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CDKN1B—melanoma	5.18e-05	0.000118	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—NOTCH1—melanoma	5.17e-05	0.000117	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CCND1—melanoma	5.16e-05	0.000117	CbGpPWpGaD
Glycopyrrolate—CHRM5—GPCR downstream signaling—AKT1—melanoma	5.12e-05	0.000116	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—NOTCH1—melanoma	5.11e-05	0.000116	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CTNNB1—melanoma	5.11e-05	0.000116	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CD80—melanoma	5.08e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CASP3—melanoma	5.07e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—APC—melanoma	5.07e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—KIT—melanoma	5.07e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CG—melanoma	5.07e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—NRAS—melanoma	5.07e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—IL2—melanoma	5.06e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CD80—melanoma	5.06e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—APC—melanoma	5.05e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CG—melanoma	5.05e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—KIT—melanoma	5.05e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—NRAS—melanoma	5.05e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—IL6—melanoma	5.04e-05	0.000114	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CD80—melanoma	5.01e-05	0.000114	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—EGF—melanoma	5.01e-05	0.000114	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MMP9—melanoma	5.01e-05	0.000114	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—APC—melanoma	5e-05	0.000114	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CG—melanoma	5e-05	0.000114	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—KIT—melanoma	5e-05	0.000114	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—NRAS—melanoma	5e-05	0.000114	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—EGF—melanoma	4.99e-05	0.000113	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CDKN1A—melanoma	4.99e-05	0.000113	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PTEN—melanoma	4.98e-05	0.000113	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—NFKB1—melanoma	4.95e-05	0.000112	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—EGF—melanoma	4.94e-05	0.000112	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CCND1—melanoma	4.94e-05	0.000112	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CTNNB1—melanoma	4.89e-05	0.000111	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—AKT1—melanoma	4.85e-05	0.00011	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—MAPK3—melanoma	4.85e-05	0.00011	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—MAPK3—melanoma	4.84e-05	0.00011	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MMP9—melanoma	4.79e-05	0.000109	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—MAPK3—melanoma	4.79e-05	0.000109	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CDKN1A—melanoma	4.78e-05	0.000108	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PTEN—melanoma	4.77e-05	0.000108	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—BRAF—melanoma	4.76e-05	0.000108	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—BRAF—melanoma	4.75e-05	0.000108	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—NFKB1—melanoma	4.74e-05	0.000108	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—BRAF—melanoma	4.7e-05	0.000107	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—AKT1—melanoma	4.65e-05	0.000106	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IGF1—melanoma	4.64e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CB—melanoma	4.63e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IGF1—melanoma	4.62e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—MAPK1—melanoma	4.62e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—EGFR—melanoma	4.62e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—MAPK1—melanoma	4.6e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—EGFR—melanoma	4.6e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PTGS2—melanoma	4.59e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IGF1—melanoma	4.58e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—MAPK1—melanoma	4.56e-05	0.000103	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—EGFR—melanoma	4.56e-05	0.000103	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—VEGFA—melanoma	4.49e-05	0.000102	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MAP2K1—melanoma	4.48e-05	0.000102	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MAP2K1—melanoma	4.47e-05	0.000101	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CD—melanoma	4.45e-05	0.000101	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—STAT3—melanoma	4.45e-05	0.000101	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CD—melanoma	4.44e-05	0.000101	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—NRAS—melanoma	4.44e-05	0.000101	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MAP2K1—melanoma	4.43e-05	0.000101	CbGpPWpGaD
Glycopyrrolate—CHRM1—GPCR downstream signaling—PIK3CA—melanoma	4.41e-05	0.0001	CbGpPWpGaD
Glycopyrrolate—CHRM3—GPCR downstream signaling—PIK3CA—melanoma	4.4e-05	9.99e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CD—melanoma	4.4e-05	9.98e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—KRAS—melanoma	4.36e-05	9.9e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—GPCR downstream signaling—PIK3CA—melanoma	4.36e-05	9.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—KRAS—melanoma	4.35e-05	9.87e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—KRAS—melanoma	4.31e-05	9.78e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—VEGFA—melanoma	4.3e-05	9.77e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—FGF2—melanoma	4.27e-05	9.68e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—STAT3—melanoma	4.26e-05	9.68e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—FGF2—melanoma	4.25e-05	9.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MAPK3—melanoma	4.25e-05	9.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—NRAS—melanoma	4.25e-05	9.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—FGF2—melanoma	4.21e-05	9.56e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MYC—melanoma	4.14e-05	9.39e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MAPK3—melanoma	4.07e-05	9.24e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MAPK1—melanoma	4.05e-05	9.19e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—EGFR—melanoma	4.04e-05	9.18e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—PIK3CA—melanoma	4.01e-05	9.1e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PTEN—melanoma	4e-05	9.08e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—PIK3CA—melanoma	3.99e-05	9.07e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MDM2—melanoma	3.99e-05	9.06e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MDM2—melanoma	3.98e-05	9.03e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MYC—melanoma	3.96e-05	8.99e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—PIK3CA—melanoma	3.96e-05	8.98e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MDM2—melanoma	3.94e-05	8.94e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—ERBB2—melanoma	3.93e-05	8.93e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—ERBB2—melanoma	3.92e-05	8.91e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—ERBB2—melanoma	3.88e-05	8.82e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CB—melanoma	3.88e-05	8.82e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MAPK1—melanoma	3.87e-05	8.8e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—EGFR—melanoma	3.87e-05	8.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CB—melanoma	3.87e-05	8.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CB—melanoma	3.83e-05	8.7e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—KRAS—melanoma	3.82e-05	8.68e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CXCL8—melanoma	3.73e-05	8.47e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CXCL8—melanoma	3.72e-05	8.45e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—HRAS—melanoma	3.71e-05	8.42e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—HRAS—melanoma	3.7e-05	8.39e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CXCL8—melanoma	3.68e-05	8.36e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—HRAS—melanoma	3.66e-05	8.31e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—KRAS—melanoma	3.66e-05	8.31e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CDKN1B—melanoma	3.64e-05	8.27e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CDKN1B—melanoma	3.63e-05	8.25e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—GPCR downstream signaling—AKT1—melanoma	3.6e-05	8.18e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CDKN1B—melanoma	3.6e-05	8.17e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—GPCR downstream signaling—AKT1—melanoma	3.59e-05	8.16e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CASP3—melanoma	3.57e-05	8.11e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IL2—melanoma	3.57e-05	8.1e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CASP3—melanoma	3.56e-05	8.08e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—GPCR downstream signaling—AKT1—melanoma	3.56e-05	8.08e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IL2—melanoma	3.55e-05	8.07e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—IL6—melanoma	3.55e-05	8.06e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—IL6—melanoma	3.54e-05	8.03e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CASP3—melanoma	3.53e-05	8e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IL2—melanoma	3.52e-05	7.99e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PIK3CA—melanoma	3.51e-05	7.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—IL6—melanoma	3.5e-05	7.95e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CCND1—melanoma	3.48e-05	7.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CCND1—melanoma	3.47e-05	7.87e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CTNNB1—melanoma	3.44e-05	7.82e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CTNNB1—melanoma	3.43e-05	7.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CCND1—melanoma	3.43e-05	7.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CTNNB1—melanoma	3.4e-05	7.72e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—TP53—melanoma	3.4e-05	7.71e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MMP9—melanoma	3.37e-05	7.66e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MMP9—melanoma	3.36e-05	7.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CDKN1A—melanoma	3.36e-05	7.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3CA—melanoma	3.36e-05	7.63e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PTEN—melanoma	3.36e-05	7.62e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CDKN1A—melanoma	3.35e-05	7.61e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PTEN—melanoma	3.34e-05	7.59e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—NFKB1—melanoma	3.34e-05	7.58e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MMP9—melanoma	3.33e-05	7.56e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—NFKB1—melanoma	3.33e-05	7.56e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CDKN1A—melanoma	3.32e-05	7.54e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PTEN—melanoma	3.31e-05	7.52e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—NFKB1—melanoma	3.3e-05	7.48e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—AKT1—melanoma	3.27e-05	7.43e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—AKT1—melanoma	3.26e-05	7.41e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—TP53—melanoma	3.25e-05	7.38e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—HRAS—melanoma	3.25e-05	7.37e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—AKT1—melanoma	3.23e-05	7.34e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—HRAS—melanoma	3.11e-05	7.06e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—IL6—melanoma	3.11e-05	7.06e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—VEGFA—melanoma	3.03e-05	6.88e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—VEGFA—melanoma	3.02e-05	6.86e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—STAT3—melanoma	3e-05	6.81e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—NRAS—melanoma	2.99e-05	6.8e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—VEGFA—melanoma	2.99e-05	6.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—STAT3—melanoma	2.99e-05	6.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—NRAS—melanoma	2.98e-05	6.78e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—IL6—melanoma	2.98e-05	6.76e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—STAT3—melanoma	2.96e-05	6.73e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—NRAS—melanoma	2.95e-05	6.71e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—AKT1—melanoma	2.87e-05	6.51e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MAPK3—melanoma	2.87e-05	6.51e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MAPK3—melanoma	2.86e-05	6.49e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MAPK3—melanoma	2.83e-05	6.43e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CA—melanoma	2.82e-05	6.41e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MYC—melanoma	2.79e-05	6.33e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MYC—melanoma	2.78e-05	6.31e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MYC—melanoma	2.75e-05	6.25e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—AKT1—melanoma	2.75e-05	6.24e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MAPK1—melanoma	2.73e-05	6.19e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—EGFR—melanoma	2.73e-05	6.19e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MAPK1—melanoma	2.72e-05	6.17e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—EGFR—melanoma	2.72e-05	6.17e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MAPK1—melanoma	2.69e-05	6.11e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—EGFR—melanoma	2.69e-05	6.11e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—KRAS—melanoma	2.58e-05	5.85e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—KRAS—melanoma	2.57e-05	5.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—KRAS—melanoma	2.54e-05	5.77e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CA—melanoma	2.37e-05	5.37e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CA—melanoma	2.36e-05	5.36e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CA—melanoma	2.34e-05	5.31e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—AKT1—melanoma	2.31e-05	5.23e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—TP53—melanoma	2.29e-05	5.2e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—TP53—melanoma	2.28e-05	5.18e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—TP53—melanoma	2.26e-05	5.13e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—HRAS—melanoma	2.19e-05	4.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—HRAS—melanoma	2.18e-05	4.96e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—HRAS—melanoma	2.16e-05	4.91e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IL6—melanoma	2.1e-05	4.76e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IL6—melanoma	2.09e-05	4.74e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IL6—melanoma	2.07e-05	4.7e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—AKT1—melanoma	1.93e-05	4.39e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—AKT1—melanoma	1.93e-05	4.38e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—AKT1—melanoma	1.91e-05	4.33e-05	CbGpPWpGaD
